vs
Embecta Corp.（EMBC）与Liberty Broadband Corp（LBRDA）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是Liberty Broadband Corp的1.0倍（$261.2M vs $261.0M），Liberty Broadband Corp净利率更高（146.7% vs 16.9%，领先129.9%），Liberty Broadband Corp同比增速更快（6.1% vs -0.3%），Liberty Broadband Corp自由现金流更多（$37.0M vs $16.6M），过去两年Liberty Broadband Corp的营收复合增速更高（4.3% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
EMBC vs LBRDA — 直观对比
营收规模更大
EMBC
是对方的1.0倍
$261.0M
营收增速更快
LBRDA
高出6.4%
-0.3%
净利率更高
LBRDA
高出129.9%
16.9%
自由现金流更多
LBRDA
多$20.4M
$16.6M
两年增速更快
LBRDA
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $261.0M |
| 净利润 | $44.1M | $383.0M |
| 毛利率 | 61.9% | — |
| 营业利润率 | 31.9% | 15.7% |
| 净利率 | 16.9% | 146.7% |
| 营收同比 | -0.3% | 6.1% |
| 净利润同比 | — | 96.4% |
| 每股收益（稀释后） | $0.74 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCLBRDA
| Q4 25 | $261.2M | — | ||
| Q3 25 | $264.0M | — | ||
| Q2 25 | $295.5M | $261.0M | ||
| Q1 25 | $259.0M | $266.0M | ||
| Q4 24 | $261.9M | $263.0M | ||
| Q3 24 | $286.1M | $262.0M | ||
| Q2 24 | $272.5M | $246.0M | ||
| Q1 24 | $287.2M | $245.0M |
净利润EMBCLBRDA
| Q4 25 | $44.1M | — | ||
| Q3 25 | $26.4M | — | ||
| Q2 25 | $45.5M | $383.0M | ||
| Q1 25 | $23.5M | $268.0M | ||
| Q4 24 | $0 | $291.0M | ||
| Q3 24 | $14.6M | $142.0M | ||
| Q2 24 | $14.7M | $195.0M | ||
| Q1 24 | $28.9M | $241.0M |
毛利率EMBCLBRDA
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 64.6% | — |
营业利润率EMBCLBRDA
| Q4 25 | 31.9% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 31.8% | 15.7% | ||
| Q1 25 | 24.3% | 16.2% | ||
| Q4 24 | 11.0% | 4.9% | ||
| Q3 24 | 9.2% | 11.5% | ||
| Q2 24 | 20.5% | 8.5% | ||
| Q1 24 | 13.6% | 11.4% |
净利率EMBCLBRDA
| Q4 25 | 16.9% | — | ||
| Q3 25 | 10.0% | — | ||
| Q2 25 | 15.4% | 146.7% | ||
| Q1 25 | 9.1% | 100.8% | ||
| Q4 24 | — | 110.6% | ||
| Q3 24 | 5.1% | 54.2% | ||
| Q2 24 | 5.4% | 79.3% | ||
| Q1 24 | 10.1% | 98.4% |
每股收益（稀释后）EMBCLBRDA
| Q4 25 | $0.74 | — | ||
| Q3 25 | $0.44 | — | ||
| Q2 25 | $0.78 | $2.68 | ||
| Q1 25 | $0.40 | $1.87 | ||
| Q4 24 | $0.00 | $2.04 | ||
| Q3 24 | $0.24 | $0.99 | ||
| Q2 24 | $0.25 | $1.36 | ||
| Q1 24 | $0.50 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $180.0M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $-613.1M | $10.4B |
| 总资产 | $1.1B | $16.6B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资EMBCLBRDA
| Q4 25 | $201.3M | — | ||
| Q3 25 | $225.5M | — | ||
| Q2 25 | $230.6M | $180.0M | ||
| Q1 25 | $209.3M | $226.0M | ||
| Q4 24 | $210.0M | $163.0M | ||
| Q3 24 | $267.5M | $168.0M | ||
| Q2 24 | $275.1M | $73.0M | ||
| Q1 24 | $299.8M | $108.0M |
总债务EMBCLBRDA
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | $1.6B | $3.7B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | — | $3.6B |
股东权益EMBCLBRDA
| Q4 25 | $-613.1M | — | ||
| Q3 25 | $-650.6M | — | ||
| Q2 25 | $-669.6M | $10.4B | ||
| Q1 25 | $-736.2M | $10.1B | ||
| Q4 24 | $-768.8M | $9.8B | ||
| Q3 24 | $-738.3M | $9.5B | ||
| Q2 24 | $-763.7M | $9.3B | ||
| Q1 24 | $-769.6M | $9.1B |
总资产EMBCLBRDA
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.2B | $16.6B | ||
| Q1 25 | $1.1B | $17.0B | ||
| Q4 24 | $1.1B | $16.7B | ||
| Q3 24 | $1.3B | $16.3B | ||
| Q2 24 | $1.3B | $16.0B | ||
| Q1 24 | $1.2B | $15.7B |
负债/权益比EMBCLBRDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $91.0M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $37.0M |
| 自由现金流率自由现金流/营收 | 6.4% | 14.2% |
| 资本支出强度资本支出/营收 | 0.2% | 20.7% |
| 现金转化率经营现金流/净利润 | 0.39× | 0.24× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $-49.0M |
8季度趋势，按日历期对齐
经营现金流EMBCLBRDA
| Q4 25 | $17.2M | — | ||
| Q3 25 | $84.0M | — | ||
| Q2 25 | $81.2M | $91.0M | ||
| Q1 25 | $31.8M | $78.0M | ||
| Q4 24 | $-5.3M | $1.0M | ||
| Q3 24 | $26.6M | $24.0M | ||
| Q2 24 | $-2.1M | $27.0M | ||
| Q1 24 | $24.3M | $52.0M |
自由现金流EMBCLBRDA
| Q4 25 | $16.6M | — | ||
| Q3 25 | $76.7M | — | ||
| Q2 25 | $80.8M | $37.0M | ||
| Q1 25 | $31.7M | $13.0M | ||
| Q4 24 | $-6.8M | $-63.0M | ||
| Q3 24 | — | $-36.0M | ||
| Q2 24 | $-11.8M | $-35.0M | ||
| Q1 24 | $20.9M | $-9.0M |
自由现金流率EMBCLBRDA
| Q4 25 | 6.4% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 27.3% | 14.2% | ||
| Q1 25 | 12.2% | 4.9% | ||
| Q4 24 | -2.6% | -24.0% | ||
| Q3 24 | — | -13.7% | ||
| Q2 24 | -4.3% | -14.2% | ||
| Q1 24 | 7.3% | -3.7% |
资本支出强度EMBCLBRDA
| Q4 25 | 0.2% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 0.1% | 20.7% | ||
| Q1 25 | 0.0% | 24.4% | ||
| Q4 24 | 0.6% | 24.3% | ||
| Q3 24 | 0.0% | 22.9% | ||
| Q2 24 | 3.6% | 25.2% | ||
| Q1 24 | 1.2% | 24.9% |
现金转化率EMBCLBRDA
| Q4 25 | 0.39× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | 0.24× | ||
| Q1 25 | 1.35× | 0.29× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 1.82× | 0.17× | ||
| Q2 24 | -0.14× | 0.14× | ||
| Q1 24 | 0.84× | 0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
LBRDA
暂无分部数据
